107 related articles for article (PubMed ID: 24666791)
1. Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries.
Unniachan S; Bash LD; Khovidhunkit W; Sri RZ; Vicaldo E; Recto C; Ambegaonkar BM
Int J Clin Pract; 2014 Aug; 68(8):1010-9. PubMed ID: 24666791
[TBL] [Abstract][Full Text] [Related]
2. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V
Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
[TBL] [Abstract][Full Text] [Related]
3. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.
Ambegaonkar BM; Bash LD; Chirovsky DR; Jameson K; Grant S; Nocea G; Pettersson B; Sazonov V
Eur J Intern Med; 2013 Oct; 24(7):656-63. PubMed ID: 23953848
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
[TBL] [Abstract][Full Text] [Related]
5. Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.
Hsu TY; Chirovsky D; Moy FM; Ambegaonkar BM
Clin Ther; 2013 Apr; 35(4):450-60. PubMed ID: 23481458
[TBL] [Abstract][Full Text] [Related]
6. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.
Khovidhunkit W; Silaruks S; Chaithiraphan V; Ongphiphadhanakul B; Sritara P; Nimitphong H; Benjanuwattra T; Ambegaonkar BM
Angiology; 2012 Oct; 63(7):528-34. PubMed ID: 22222187
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
[TBL] [Abstract][Full Text] [Related]
9. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
10. Impact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event rates.
Cziraky MJ; Tan H; Bullano MF; Yu J; Schiebinger R; Willey VJ
Int J Clin Pract; 2011 Apr; 65(4):425-35. PubMed ID: 21401832
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA).
Pettersson B; Ambegaonkar B; Sazonov V; Martinell M; Stålhammar J; Wändell P
BMC Public Health; 2010 Nov; 10():737. PubMed ID: 21114824
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
Tóth PP; Potter D; Ming EE
J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
[TBL] [Abstract][Full Text] [Related]
14. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.
Jameson K; Amber V; D'Oca K; Mills D; Giles A; Ambegaonkar B
Int J Clin Pract; 2013 Dec; 67(12):1228-37. PubMed ID: 23944233
[TBL] [Abstract][Full Text] [Related]
15. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
16. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
17. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).
Raal FJ; Blom DJ; Naidoo S; Bramlage P; Brudi P
Cardiovasc J Afr; 2013 Sep; 24(8):330-8. PubMed ID: 24240385
[TBL] [Abstract][Full Text] [Related]
19. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
